{"type":"trials","record":{"id":34,"source_id":"clinicaltrials-gov","external_id":"NCT00723255","title":"Bevacizumab and Temsirolimus in Treating Patients With Recurrent or Persistent Endometrial Cancer","brief_summary":"This phase II trial is studying the side effects of giving bevacizumab together with temsirolimus and to see how well it works in treating patients with recurrent or persistent endometrial cancer. Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Temsirolimus may stop the growth of tumor cells by blocking some of the enzymes needed for their growth. Giving bevacizumab together with temsirolimus may kill more tumor cells.","overall_status":"Completed","phases":["PHASE2"],"study_type":"INTERVENTIONAL","sponsor":"National Cancer Institute (NCI)","enrollment":53,"countries":["United States"],"start_date":"2008-09-01","completion_date":"2016-01-25","last_update_date":"2019-07-23","source_url":"https://clinicaltrials.gov/study/NCT00723255","editorial_summary":"A registered PHASE2 study indexed because it matched monitored longevity research terms. Registry status: Completed. Registration does not establish safety or effectiveness.","first_seen_at":"2026-09-14T02:44:58.543517+00:00","last_seen_at":"2026-09-15T00:18:31.508+00:00","metadata":{"acronym":null,"organization":"National Cancer Institute (NCI)","source_has_results":true},"controlled_terms":[],"relevance_confidence":80,"source_quality_score":100,"freshness_score":50,"publication_state":"published","match_explanation":"Published automatically with 80% topic confidence after controlled-term evaluation.","quality_checked_at":"2026-09-15T02:15:56.576005+00:00","duplicate_cluster_key":"registry:nct00723255","duplicate_of_id":null,"clinical_trial_topics":[{"topic_slug":"rapamycin","is_published":true,"match_reasons":["Legacy trial evaluated automatically against controlled title, summary, and longevity-context rules."],"matched_fields":["title"],"relevance_score":80,"intelligence_topics":{"name":"Rapamycin","slug":"rapamycin"}}],"content_sources":{"name":"ClinicalTrials.gov","homepage_url":"https://clinicaltrials.gov/"}},"canonical_url":"https://www.immortal.life/trials/34","automation_disclosure":"Generated automatically from cited source metadata. No scientist, clinician, researcher, editor, or human reviewer evaluates this publication before release."}